Kymera Therapeutics

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL-2 inhibitor venetoclax in model of venetoclax-resistant AML KT-253 also active in other hematologic malignancies including DLBCL WATERTOWN, Mass.,